The Chinese company reveals a new parenteral formulation manufacturing line has begun operations, and that it has signed a deal for the deployment of a robotic system for oral solid dosage forms.
A company leader advises that the growing need for high-potency active pharmaceutical ingredients calls for CDMOs that consistently deliver quality at scale.
This month’s news on hires, promotions, acquisitions, expansions, and funding includes items about Syneos Health, ProSciento, Phastar, CPhI, Immunai, and other key industry players.
The company’s Shanghai facility passes the European regulator’s inspection with no ‘critical’ or ‘major’ findings regarding the commercial products produced at the site.
As WuXi STA expands its facility footprint in China, a VP of the company explains how global regulatory approvals fit with strategic plans for services to be concentrated geographically.
WuXi STA becomes the preferred CDMO partner for Beta Pharma as the company launches a Phase II clinical trial in China and begins preclinical research for an additional target.
